G1 to S cell cycle control (WP45)

Homo sapiens

In the G1 phase there are two types of DNA damage responses, the p53-dependent and the p53-independent pathways. The p53-dependent responses inhibit CDKs through the up-regulation of genes encoding CKIs mediated by the p53 protein, whereas the p53-independent mechanisms inhibit CDKs through the inhibitory T14Y15 phosphorylation of Cdk2. Failure of DNA damage checkpoints in G1 leads to mutagenic replication of damaged templates and other replication defects. Source: Reactome Proteins on this pathway have targeted assays available via the [https://assays.cancer.gov/available_assays?wp_id=WP45 CPTAC Assay Portal]
last edited

Authors

Alexander C. Zambon , Kristina Hanspers , Mark Scott , Alex Pico , Christine Chichester , Zahra Roudbari , Ryan Miller , Denise Slenter , and Egon Willighagen

Cited In

Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.

Organism

Homo sapiens

Communities

CPTAC PancCanNet

Annotations

Pathway Ontology: G1/S DNA damage checkpoint pathway cell cycle checkpoint pathway

Participants

Label Type Compact Identifier Comment
RB1 GeneProduct ncbigene:5925
E2F2 GeneProduct ncbigene:1870
E2F1 GeneProduct ncbigene:1869
POLE GeneProduct ncbigene:5426
CDKN1B GeneProduct ncbigene:1027
CDK6 GeneProduct ncbigene:1021
PCNA GeneProduct ncbigene:5111
CDK4 GeneProduct ncbigene:1019
CDKN1A GeneProduct ncbigene:1026
CDC45L GeneProduct ncbigene:8318
CDKN2A GeneProduct ncbigene:1029
CDK1 GeneProduct ncbigene:983
CDK2 GeneProduct ensembl:ENSG00000123374
TP53 GeneProduct ncbigene:7157
PRIM2A GeneProduct ncbigene:5558
CDKN1C GeneProduct ncbigene:1028
CCND2 GeneProduct ncbigene:894
CCNE1 GeneProduct ncbigene:898
CDK2 GeneProduct ensembl:ENSG00000123374
CREB3L4 GeneProduct ncbigene:148327
CDKN2B GeneProduct ncbigene:1030
MDM2 GeneProduct ncbigene:4193
CDK7 GeneProduct ncbigene:1022
CCNG2 GeneProduct ncbigene:901
RPA2 GeneProduct ncbigene:6118
CDK4 GeneProduct ncbigene:1019
CDK2 GeneProduct ncbigene:1017
TP53 GeneProduct ncbigene:7157
CDKN2D GeneProduct ncbigene:1032
CDK7 GeneProduct ncbigene:1022
CREB3 GeneProduct ncbigene:10488
CREB3L3 GeneProduct ncbigene:84699
MYT1 GeneProduct ncbigene:4661
TFDP2 GeneProduct ncbigene:7029
CCNB1 GeneProduct ncbigene:891
CCND3 GeneProduct ncbigene:896
CCND1 GeneProduct ncbigene:595
CCNH GeneProduct ncbigene:902
MYC GeneProduct ncbigene:4609
RPA3 GeneProduct ncbigene:6119
MCM4 GeneProduct ncbigene:4173
MCM3 GeneProduct ncbigene:4172
CREBL1 GeneProduct ncbigene:1388
ORC1L GeneProduct ncbigene:4998
MCM6 GeneProduct ncbigene:4175
MCM7 GeneProduct ncbigene:4176
MCM2 GeneProduct ncbigene:4171
ORC3L GeneProduct ncbigene:23595
CDKN2C GeneProduct ncbigene:1031
POLE2 GeneProduct ncbigene:5427
MNAT1 GeneProduct ncbigene:4331
ORC6L GeneProduct ncbigene:23594
CDC2A GeneProduct ncbigene:1017
MCM5 GeneProduct ncbigene:4174
ORC2L GeneProduct ncbigene:4999
E2F3 GeneProduct ncbigene:1871
CDK6 GeneProduct ncbigene:1021
RPA1 GeneProduct ncbigene:6117
CREB1 GeneProduct ncbigene:1385
TFDP1 GeneProduct ncbigene:7027
WEE1 GeneProduct ncbigene:7465
ATM GeneProduct ncbigene:472
CREB3L1 GeneProduct ncbigene:90993
GADD45A GeneProduct ncbigene:1647
POLA2 GeneProduct ncbigene:23649
ORC4L GeneProduct ncbigene:5000
CCNE1 GeneProduct ncbigene:898
PRIM1 GeneProduct ncbigene:5557
CDC25A GeneProduct ncbigene:993
CCNE1 GeneProduct ncbigene:898
CCNA1 GeneProduct ncbigene:8900
ORC5L GeneProduct ncbigene:5001
CCNE2 GeneProduct ncbigene:9134
CCND1 GeneProduct ncbigene:595
CDK4 GeneProduct ncbigene:1019
CDK6 GeneProduct ncbigene:1021
CCND1 GeneProduct ncbigene:595
CDK4 GeneProduct ncbigene:1019
CDK6 GeneProduct ncbigene:1021
RB1 GeneProduct ncbigene:5925
E2F2 GeneProduct ncbigene:1870
E2F1 GeneProduct ncbigene:1869
E2F3 GeneProduct ncbigene:1871
TFDP2 GeneProduct ncbigene:7029
TFDP1 GeneProduct ncbigene:7027
CDKN1B GeneProduct ensembl:ENSG00000111276

References

  1. Maeda T, Hanna AN, Sim AB, Chua PP, Chong MT, Tron VA. GADD45 regulates G2/M arrest, DNA repair, and cell death in keratinocytes following ultraviolet exposure. J Invest Dermatol. 2002 Jul;119(1):22–6. PubMed Europe PMC Scholia